Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphoma.

HemaSphere·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026

Related Experiment Video

Updated: May 24, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

Primary CNS lymphoma.

Andrés J M Ferreri1, Emerenziana Marturano

  • 1Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy. andres.ferreri@hsr.it

Best Practice & Research. Clinical Haematology
|March 14, 2012
PubMed
Summary

Primary CNS lymphoma (PCNSL) treatment faces challenges due to limited knowledge and patient conditions. Balancing intensified therapy for cure versus de-escalation to avoid neurotoxicity is key for this aggressive brain tumor.

Area of Science:

  • Neuro-oncology
  • Hematology
  • Radiation Oncology

Background:

  • Primary CNS lymphoma (PCNSL) is a rare, aggressive brain tumor with poor outcomes.
  • Limited understanding of PCNSL biology and molecular characteristics hinders targeted therapy development.
  • Patient comorbidities and poor performance status complicate enrollment in clinical trials.

Purpose of the Study:

  • To review current treatment strategies for PCNSL.
  • To discuss the challenges of chemotherapy penetration across the blood-brain barrier (BBB).
  • To explore the role of radiotherapy and novel approaches like high-dose chemotherapy with stem cell transplantation.

Main Methods:

  • Review of existing literature on PCNSL treatment modalities.
  • Analysis of the efficacy and toxicity of chemoradiation therapy.

More Related Videos

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

Related Experiment Videos

Last Updated: May 24, 2026

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)
08:46

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG)

Published on: March 7, 2017

  • Discussion of alternative consolidation strategies post-chemotherapy.

    • Main Results:

    • Chemoradiation offers better efficacy but carries a high risk of severe neurotoxicity.
    • The blood-brain barrier (BBB) limits chemotherapy effectiveness in CNS sanctuaries.
    • Whole-brain radiotherapy, while consolidative, increases neurotoxicity risk.

    Conclusions:

    • PCNSL treatment necessitates balancing efficacy with neurotoxicity.
    • High-dose chemotherapy with autologous stem cell transplantation is being investigated as an alternative to radiotherapy.
    • Future progress depends on advancing molecular knowledge and developing less toxic, more effective therapies.